The senior management currently consists of the CEO, CFO, Head of Regulatory Affairs, Head of Clinical Development, Head of Research and CMC, CMO, CSO and CCO.
JAKOB LINDBERG, Med Lic
Chief Executive Officer
Jakob Lindberg was appointed as CEO in 2011.
In addition to being CEO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies.
Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.
Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University.
Holdings in Oncopeptides: 560,831 shares (545,531 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 175 employee options* and 250,050 options**.
Other current positions: Director of Affibody Medical AB and Lindberg Life-Science AB. Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.
ANDERS MARTIN-LÖF, MSc
Chief Financial Officer
Anders Martin-Löf was appointed CFO in 2018.
Anders was previously CFO of Wilson Therapeutics AB and RaySearch Laboratories AB, both listed on Nasdaq Stockholm. He held various business development positions for Swedish Orphan Biovitrum where he also served as Director of Investor Relations. In addition he has worked as a management consultant at the Boston Consulting Group, Cell Network and as co-founder and CEO of ScienceCap.
Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BA in Business Administration and Economics, from Stockholm University.
Holdings in Oncopeptides: 5,000 shares and 212,118 options**.
Other current positions: Director of Cantargia AB and alternate director of Lisa Martin-Löf konsultbyrå AB and alternate director of Oncopeptides Incentive AB.
CHRISTIAN JACQUES, MD, MSc
EVP and Chief Scientific Officer
Christian Jacques was appointed EVP and Chief Scientific Officer in 2018.
In addition to being EVP and CSO of Oncopeptides, Christian is Chief Scientific Officer at Pharma Biotech Consultants LLC, which provides consulting services to companies within the area of hemato-oncology.
Christian has previously held roles at a number of life sciences companies including as Vice President Clinical Development at Celgene, where he was in charge of the multiple myeloma clinical development for Celgene products and got approval of pomalidomide (Pomalyst or Imnovid) in the US, EU and several other key countries. He also led the global clinical development for Revlimid. Christian also held roles at Novartis, Johnson & Johnson, Aventis (Formerly Rhone-Poulenc) and Pierre Fabre Oncologie, all within Oncology.
He has more than 54 publications in peer-reviewed journals or at major congresses.
Christian holds an MD degree and Internal Medicine degree from Université Catholique de Louvain, Belgium. Christian has been a hospital practitioner for 10 years.
Holdings in Oncopeptides: 223,280 options**
Other current positions: Dr Jacques is a member of American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
ELISABETH AUGUSTSSON, MSc
Head of Regulatory Affairs
Elisabeth Augustsson was appointed as Head of Regulatory Affairs in 2015.
In addition to being Head of Regulatory Affairs of Oncopeptides, Elisabeth is the President and Founder of Restracom, which provides consulting services to pharmaceutical companies in the area of regulatory strategies and communication with regulatory authorities.
Elisabeth has previously held roles at a number of life sciences companies including Pharmacia&Upjohn, Medivir AB, Biovitrum AB, Karo Bio AB and Alexion AB.
Elisabeth holds an MSc Pharm from Uppsala University.
Holdings in Oncopeptides: 93,117 options**.
Other current positions: Chairman of the Board and CEO of Restracom AB.
EVA NORDSTRÖM, MSc Pharm
Vice President, Head of Clinical Development
Eva Nordström was appointed as Head of Clinical Development in 2012.
Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.
Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.
Holdings in Oncopeptides: 120,200 shares, 33 employee options* and 117,283 options**.
Other current positions: Alternate Director of Utilica AB.
FREDRIK LEHMANN, PhD
Head of Research and CMC (Chemistry, Manufacturing & Control)
Fredrik Lehmann was appointed Head of CMC in 2010 and Head of Research in 2018.
In addition to being Head of CMC for Oncopeptides, Fredrik is an independent consultant within preclinical research and CMC.
Fredrik has previously held positions at a number of life sciences businesses including Pharmacia, Personal Chemistry, Biovitrum and Recipharm. He has also co-founded six life science companies.
Fredrik holds a PhD in medicinal chemistry from Gothenburg University.
Holdings in Oncopeptides: 17,652 shares (16,652 directly owned, 1,000 indirectly owned through OT Lehmann Holding AB), 13 employee options* and 82,017 options**.
Other current positions: Director and CEO of OT Pharmaceuticals AB. Board member of OT Lehmann Holding AB and Chariman of the board of Synartro AB. Board member of Sprint Bioscience and member of the Scientific Advisory Board at Akthelia Pharmaceuticals.
JOSEPH HORVAT, BSc
President North America
Joseph Horvat was appointed President North America in 2019.
Before Joseph joined Oncopeptides, he served for nine years in different positions at EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany), most recently as Senior Vice President of the Oncology Business Unit with responsibility for driving the US oncology product portfolio. He previously played a critical role in the development of EMD Serono’s commercial build up in antizipation of an upcoming launch. As part of his responsibility, Joseph created a strong culture and attracted talent that incrementally added to the success of the franchise and set the foundation for EMD Serono’s launch of its first immuno-oncology product.
Prior to joining EMD Serono, Joseph spent over a decade of his early career at Bristol-Myers Squibb where he held various roles of increasing responsibility across several areas including oncology, cardiovascular and neuroscience.
Holdings in Oncopeptides: Nil
KLAAS BAKKER, MD, PhD
EVP and Chief Medical Officer
Klaas Bakker was appointed as EVP and Chief Medical Officer in 2019.
Klaas has previously held roles with increasing seniority at AstraZeneca, most recently as Vice President Medical Affairs of the Global TAGRISSO/TDR Franchise in Oncology. In this role he was responsible for the global launch of osimertinib, the companies‘ largest asset across all therapeutic areas.
Klaas holds an MD and is a board certified neurosurgeon from the university of Groningen, the Netherlands, where he was clinically active until 2015. In addition, he holds a PhD in Hematology and has authored over 40 publications in international peer-reviewed journals.
Holdings in Oncopeptides: 4,800 shares and 58,190 options**.
Chief Commercial Officer
Paula Boultbee was appointed as the Chief Commercial Officer in 2016.
Paula comes with expertise that is acquired from both small and large pharmaceutical companies, most recently she was the Executive Vice President of Sales and Marketing at Pharmacyclics where she did build a team and launched their first commercial product, Imbruvica that has become a multi-billion dollar asset. She has also held positions at Novartis, Amgen and Pharmacia with growing responsibility in both sales, brand management, country and regional leadership roles; Novartis as Executive Director a leader and executer for a global launch of flagship product Glivec/Gleevec (imatinib) with $6Billon global sales.
Before joining Oncopeptides she worked as independent consult and has supported several companies in building their commercial markets that have led to successful launch, fundraising, desired acquisitions and licensing agreements.
Paula has nursing degree.
Holdings in Oncopeptides: 124,445 options**.
Other current positions: Chairman of The Max Foundation and Isofol Medical AB board member. Advisor to Monocl AB and early stage biotech companies in the Bay Area California. Paula runs PTB Consulting LLC.
* Each employee option entitles the holder to acquire 900 shares per option in the company.
** The options entitles to one share per option in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.
Holdings in Oncopeptides AB as of October 14, 2019.